Gliomas With 1p/19q Codeletion: a.k.a. Oligodendroglioma
Gliomas With 1p/19q Codeletion: a.k.a. Oligodendroglioma
复制标题
DOI：
10.1097/ppo.0b013e31818d8178
复制
发表时间：
2008-11-01
期刊：
影响因子：
2.2
通讯作者：
Jenkins, Robert
中科院分区：
文献类型：
--
作者：
Cairncross, Gregory;Jenkins, Robert
今天，所有类型胶质瘤患者的治疗建议都是基于肿瘤组织的光学显微镜评估，不考虑遗传变异性。少突胶质细胞瘤的治疗是统一的，到目前为止，没有独特的治疗方法或靶向治疗那些窝藏染色体1 p和19 q的共缺失。手术切除和放疗是少突胶质细胞瘤患者的标准治疗方法。手术可以改善症状，特别是头痛或癫痫发作，放射治疗可以控制大多数患者的肿瘤生长。从胶质母细胞瘤的随机试验推断，放疗可能会延长生存期。对于低级别少突胶质细胞瘤患者的放疗时机一直没有定论，但上级抗肿瘤治疗尚未出现。这就是说。1 p/19 q缺失的少突胶质细胞瘤对目前的治疗敏感，生长缓慢，这一认识已经影响了我们对这类胶质细胞瘤患者的治疗，产生了通过分子标记选择患者的试验。
Today, treatment recommendations for patients with all types of gliomas are based on light microscopic evaluation of tumor tissue with no allowance for genetic variability. Oligodendrogliomas are treated in a uniform manner with, as yet, no unique therapeutic approach or targeted therapy for those harboring a codeletion of chromosomes 1p and 19q. Surgical resection and radiotherapy are the standards-of-care for patients with oligodendrogliomas. Surgery improves symptoms, especially headache or seizures, and radiotherapy controls tumor growth for most patients. By extrapolation from randomized trials of glioblastoma, radiotherapy likely prolongs survival. Uncertainties persist about the timing of radiotherapy in the management of patients with low-grade oligodendrogliomas, but a superior antitumor treatment has yet to emerge. That said. the recognition that oligodendrogliomas with 1p/19q loss are sensitive to current therapies and slowly growing is already influencing our management of patients with this type of glioma, spawning trials in which patients are selected by Molecular signature.